XELOX

03/01/2009 - "XELOX-RT was feasible and showed promising efficacy when treating patients with primary inextirpable colorectal cancer, establishing high local control rate."
05/01/2007 - "Which first-line treatment is superior in advanced colorectal cancer: XELOX or pviFOX?"
04/01/2007 - "The aim of the present study was to define the feasibility and efficacy of XELOX administered through a new chronomodulated schedule in untreated advanced colorectal cancer (CRC) patients. "
11/01/2006 - "An international phase III trial (NO16966) was initiated to demonstrate the noninferiority of XELOX to FOLFOX4 for the first-line treatment of metastatic colorectal cancer. "
09/01/2012 - "Cost identification of Nordic FLIRI, Nordic FLOX, XELIRI and XELOX in first-line treatment of advanced colorectal cancer in Sweden -- a clinical practice model approach."

03/01/2010 - "The XELOX regimen shows good efficacy with an acceptable toxicity profile in advanced or recurrent gastric cancer patient."
08/14/2012 - "For patients with a preoperative diagnosis of unresectable gastric cancer, the efficacy of the FLEEOX regimen, which combines arterial with venous administration, was better than that of the XELOX regimen, using venous administration only. "
01/01/2022 - "XELOX doublet regimen versus EOX triplet regimen as first-line treatment for advanced gastric cancer: An open-labeled, multicenter, randomized, prospective phase III trial (EXELOX)."
01/01/2010 - "Phase II trial of XELOX as first-line treatment for patients with advanced gastric cancer."
08/01/2010 - "XELOX regimen can be effectively and safely applied as first-line treatment for advanced gastric cancer patients."

09/18/2019 - "Postoperative XELOX without preoperative chemoradiation is effective for rectal cancer and provides adequate 3-year DFS prospects. "
09/18/2019 - "We aimed to evaluate the efficacy of surgery and postoperative XELOX without preoperative chemoradiation for treating rectal cancer. "
02/01/2016 - "This pilot study found that neoadjuvant XELOX for locally advanced lower rectal cancer is feasible and safe. "
02/01/2016 - "Patients with clinical stage II/III lower rectal cancer underwent three cycles of XELOX followed by radical surgery. "
11/28/2011 - "Neoadjuvant chemoradiotherapy using the XELOX regimen in rectal cancer patients obviously reduced the TNM staging and improved the pathological complete response rate. "

12/01/2021 - "Multiple liver metastases appeared 4 months postoperatively, which were treated with XELOX plus BV and FOLFIRI plus BV. "
06/01/2020 - "There was no significant difference in peritoneal metastasis rates in the SOX and XELOX groups (8.6% vs 15%, respectively; P = 0.232). "
01/01/2018 - "The sandwich NACRT with XELOX regimen might reduce distant metastasis and improve the survival of LARC patients. "
04/25/2008 - "50 patients with resectable liver metastases received neoadjuvant XELOX or FOLFOX4 for six cycles (3 months). "
12/01/2022 - "CT imaging 2 years after the operation showed peritoneal dissemination and liver metastasis, and XELOX therapy was initiated. "

06/01/2013 - "[A case of metastatic colon cancer effectively treated by XELOX and IRIS]."
10/16/2019 - "Safety and efficacy of a modified XELOX adjuvant regimen for patients with operated stage III colon cancer: a Chinese single-center experience."
10/01/2017 - "However, its safety and tolerability in Asian patients is unclear; therefore, we evaluated the safety and efficacy of adjuvant XELOX in Japanese patients with curatively resected stage III colon cancer (MCSCO-1024) and present the interim safety data. "
11/10/2015 - "XELOX improved OS compared with bolus FU/FA in patients with resected stage III colon cancer after a median follow-up of almost 7 years. "
06/01/2018 - "The FACOS trial investigated the tolerability of modified FOLFOX6 (mFOLFOX6) and XELOX regimens in Japanese colon cancer patients. "